<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00746447</url>
  </required_header>
  <id_info>
    <org_study_id>SAG-27/UCR</org_study_id>
    <secondary_id>EudraCT No.: 2004-001218-15</secondary_id>
    <nct_id>NCT00746447</nct_id>
  </id_info>
  <brief_title>Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)</brief_title>
  <official_title>Double-blind, Double-dummy, Randomised, Multicentre, 12-months, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules vs. Once Daily 1.5 g Mesalazine Granules vs. Three Times Daily 0.5 g Mesalazine Granules for Maintenance of Remission in Patients With Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to study the efficacy and tolerability of once daily 3.0 g mesalazine
      granules vs. once daily 1.5 g mesalazine granules vs. three times daily 0.5 g mesalazine
      granules for maintenance of remission in patients with ulcerative colitis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients still in clinical remission at the final/withdrawal examination, with clinical relapse defined as a CAI &gt;4 with an increase of ≥3 points from baseline.</measure>
    <time_frame>week 52 or premature withdrawal</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>within 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in endoscopical remission, defined as a mucosal appearance score of ≤ 1 at final/withdrawal examination.</measure>
    <time_frame>week 52 or premature withdrawal</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">648</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <condition>Recurrence</condition>
  <arm_group>
    <arm_group_label>3.0g OD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5g OD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5g TID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesalamine granules</intervention_name>
    <description>3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;</description>
    <arm_group_label>3.0g OD</arm_group_label>
    <other_name>Salofalk granules</other_name>
    <other_name>Mesalazine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesalamine granules</intervention_name>
    <description>1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;</description>
    <arm_group_label>1.5g OD</arm_group_label>
    <other_name>Salofalk granules</other_name>
    <other_name>Mesalazine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesalamine granules</intervention_name>
    <description>0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening</description>
    <arm_group_label>0.5g TID</arm_group_label>
    <other_name>Salofalk granules</other_name>
    <other_name>Mesalazine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent,

          -  Men or women aged 18 to 75 years,

          -  Historically confirmed diagnosis of ulcerative colitis by endoscopy and histology,

          -  Patient being in remission, defined (according to Rachmilewitz) as:

        Clinical Activity Index (CAI) &lt;= 4, and Endoscopic Index (EI) &lt; 4,

          -  Extent of inflammation during last acute episode was &gt;15 cm beyond the anal margin,

          -  Last acute episode ended within 3 months prior to study entry.

        Exclusion Criteria:

          -  Crohn's disease,

          -  Prior bowel resection leading to diarrhoea,

          -  Toxic megacolon,

          -  Gastric or duodenal ulcer,

          -  Haemorrhagic diathesis,

          -  Presence of symptomatic organic disease of the gastrointestinal tract (with the
             exception of haemorrhoids or hiatal hernia),

          -  Active colorectal cancer or a history of colorectal cancer,

          -  Serious other secondary illnesses of an acute or chronic nature,

          -  Asthma,

          -  Severe impairment of renal (e.g., serum creatinine &gt; 1.5 mg/dl) and/or liver functions
             (e.g., serum transaminase [ALT and/or AST] or alkaline phosphatase &gt;=2x upper limit of
             normal [ULN]),

          -  Application of immunosuppressants within 3 months and/or corticosteroids (oral,
             intravenous [IV] or topical rectal) within 30 days prior to baseline,

          -  Application of non-steroidal anti-inflammatory drugs (NSAIDs) as long term treatment
             (i.e. &gt; 6 weeks), other than acetylsalicylic acid (&lt;= 350 mg/day), or paracetamol,

          -  Known intolerance/hypersensitivity to salicylic acid and its derivatives or to any of
             the other constituents of the study drugs,

          -  Well-founded doubt about the patient's cooperation,

          -  Existing or intended pregnancy, breast-feeding,

          -  Women of child-bearing potential without adequate contraceptive protection, e.g.,
             hormonal contraception, intrauterine device (IUD), double-barrier method of
             contraception (e.g., use of a condom and spermicide), partner has undergone vasectomy
             and subject is in monogamous relationship. The investigator is responsible for
             determining whether the subject has adequate birth control for study participation,

          -  Participation in another clinical trial within the last 30 days,simultaneous
             participation in another clinical trial, or previous participation in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Mueller, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Falk Pharma GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Kalk, Medical Dept.</name>
      <address>
        <city>Cologne</city>
        <zip>51103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Kruis W, Jonaitis L, Pokrotnieks J, Mikhailova TL, Horynski M, Bátovský M, Lozynsky YS, Zakharash Y, Rácz I, Kull K, Vcev A, Faszczyk M, Dilger K, Greinwald R, Mueller R; International Salofalk OD Study Group. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011 Feb;33(3):313-22. doi: 10.1111/j.1365-2036.2010.04537.x. Epub 2010 Dec 8.</citation>
    <PMID>21138455</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2008</study_first_submitted>
  <study_first_submitted_qc>September 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2008</study_first_posted>
  <last_update_submitted>June 25, 2012</last_update_submitted>
  <last_update_submitted_qc>June 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>maintenance</keyword>
  <keyword>5-ASA</keyword>
  <keyword>mesalamine</keyword>
  <keyword>mesalazine</keyword>
  <keyword>ulcerative colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

